这个任务要求提供一种测试方法，能够简单的检测出血友病A 中凝血因子Ⅷ和血友病B 中凝血因子IX在血液中的水平。因为现在市面上所使用的测试方法都不太方便，都不适用于诊所，而且患者也不能在家里进行自我检测。这个任务要求提供一个半定量的测试方式，需要提供可靠的血液中凝血因子水平的资料，然后根据情况分为正常，轻微，严重三种疾病状态。
“征稿件请直接上传网址：https://www.innocentive.com”
TAGS: Engineering/Design, Chemistry, Global Health, Nature, Life Sciences, Food/Agriculture, Theoretical-IP Transfer
AWARD: $25,000 USD | DEADLINE: 2/21/13 | ACTIVE SOLVERS: 27 | POSTED: 12/21/12
The Seeker requires a test that could easily be used to monitor the level of blood coagulation factors FVIII or FIX present in hemophilia A and B patients, respectively. Today, many tests are commercially available, but none are suited for convenient testing either by care providers in the clinic or by hemophilia patients at home. A semi-quantitative test is required that would provide reliable information on the blood levels of FVIII or FIX relative to a state considered as ‘Normal’, ‘Mild’ or ‘Severe’ state of disease.
This Challenge requires only a written proposal.
Detailed Description & Requirements
Background
Hemophilia A and B are inherited coagulation diseases that severely impact the quality of life of persons afflicted. Hemophilia A is caused by lack of coagulation factor VIII (FVIII), while in hemophilia B patients lack coagulation factor IX (FIX). Although the diseases are to a large extent manageable using clotting factor supplement therapies, FVIII and FIX treatment needs to be monitored in order to ensure that it meets the requirements of the individual patients’ plasma level of the coagulations factor to be supplemented. Current tests require tedious laboratory analysis, not allowing patients to achieve the frequency of testing that would facilitate good management of their disease.
The Problem
Hemophilia patients are expected to benefit from daily monitoring of their disease status (i.e. measurements of FVIII or FIX levels) to check the efficacy of their therapy and the current status of their disease.
[更多]
